Cargando…
The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections
Pseudomonas aeruginosa infections are challenging to treat due to multi-drug resistance (MDR) and the complexity of the patients affected by these serious infections. As new antibiotic therapies come on the market, limited data exist about the effectiveness of such treatments in clinical practice. I...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137796/ https://www.ncbi.nlm.nih.gov/pubmed/35625270 http://dx.doi.org/10.3390/antibiotics11050626 |
_version_ | 1784714467373744128 |
---|---|
author | Caffrey, Aisling R. Appaneal, Haley J. Liao, J. Xin Piehl, Emily C. Lopes, Vrishali Dillon, Ryan J. Puzniak, Laura A. LaPlante, Kerry L. |
author_facet | Caffrey, Aisling R. Appaneal, Haley J. Liao, J. Xin Piehl, Emily C. Lopes, Vrishali Dillon, Ryan J. Puzniak, Laura A. LaPlante, Kerry L. |
author_sort | Caffrey, Aisling R. |
collection | PubMed |
description | Pseudomonas aeruginosa infections are challenging to treat due to multi-drug resistance (MDR) and the complexity of the patients affected by these serious infections. As new antibiotic therapies come on the market, limited data exist about the effectiveness of such treatments in clinical practice. In this comparative effectiveness study of ceftolozane/tazobactam versus aminoglycoside- or polymyxin-based therapies among hospitalized patients with positive MDR P. aeruginosa cultures, we identified 57 patients treated with ceftolozane/tazobactam compared with 155 patients treated with aminoglycoside- or polymyxin-based regimens. Patients treated with ceftolozane/tazobactam were younger (mean age 67.5 vs. 71.1, p = 0.03) and had a higher comorbidity burden prior to hospitalization (median Charlson 5 vs. 3, p = 0.01) as well as higher rates of spinal cord injury (38.6% vs. 21.9%, p = 0.02) and P. aeruginosa-positive bone/joint cultures (12.3% vs. 0.7%, p < 0.0001). Inpatient mortality was significantly lower in the ceftolozane/tazobactam group compared with aminoglycosides or polymyxins (15.8% vs. 27.7%, adjusted odds ratio 0.39, 95% confidence interval 0.16–0.93). There were no significant differences observed for the other outcomes assessed. In hospitalized patients with MDR P. aeruginosa, inpatient mortality was 61% lower among patients treated with ceftolozane/tazobactam compared to those treated with aminoglycoside- or polymyxin-based regimens. |
format | Online Article Text |
id | pubmed-9137796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91377962022-05-28 The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections Caffrey, Aisling R. Appaneal, Haley J. Liao, J. Xin Piehl, Emily C. Lopes, Vrishali Dillon, Ryan J. Puzniak, Laura A. LaPlante, Kerry L. Antibiotics (Basel) Article Pseudomonas aeruginosa infections are challenging to treat due to multi-drug resistance (MDR) and the complexity of the patients affected by these serious infections. As new antibiotic therapies come on the market, limited data exist about the effectiveness of such treatments in clinical practice. In this comparative effectiveness study of ceftolozane/tazobactam versus aminoglycoside- or polymyxin-based therapies among hospitalized patients with positive MDR P. aeruginosa cultures, we identified 57 patients treated with ceftolozane/tazobactam compared with 155 patients treated with aminoglycoside- or polymyxin-based regimens. Patients treated with ceftolozane/tazobactam were younger (mean age 67.5 vs. 71.1, p = 0.03) and had a higher comorbidity burden prior to hospitalization (median Charlson 5 vs. 3, p = 0.01) as well as higher rates of spinal cord injury (38.6% vs. 21.9%, p = 0.02) and P. aeruginosa-positive bone/joint cultures (12.3% vs. 0.7%, p < 0.0001). Inpatient mortality was significantly lower in the ceftolozane/tazobactam group compared with aminoglycosides or polymyxins (15.8% vs. 27.7%, adjusted odds ratio 0.39, 95% confidence interval 0.16–0.93). There were no significant differences observed for the other outcomes assessed. In hospitalized patients with MDR P. aeruginosa, inpatient mortality was 61% lower among patients treated with ceftolozane/tazobactam compared to those treated with aminoglycoside- or polymyxin-based regimens. MDPI 2022-05-06 /pmc/articles/PMC9137796/ /pubmed/35625270 http://dx.doi.org/10.3390/antibiotics11050626 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Caffrey, Aisling R. Appaneal, Haley J. Liao, J. Xin Piehl, Emily C. Lopes, Vrishali Dillon, Ryan J. Puzniak, Laura A. LaPlante, Kerry L. The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections |
title | The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections |
title_full | The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections |
title_fullStr | The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections |
title_full_unstemmed | The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections |
title_short | The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections |
title_sort | comparative effectiveness of ceftolozane/tazobactam versus aminoglycoside- or polymyxin-based regimens in multi-drug-resistant pseudomonas aeruginosa infections |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137796/ https://www.ncbi.nlm.nih.gov/pubmed/35625270 http://dx.doi.org/10.3390/antibiotics11050626 |
work_keys_str_mv | AT caffreyaislingr thecomparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT appanealhaleyj thecomparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT liaojxin thecomparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT piehlemilyc thecomparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT lopesvrishali thecomparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT dillonryanj thecomparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT puzniaklauraa thecomparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT laplantekerryl thecomparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT caffreyaislingr comparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT appanealhaleyj comparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT liaojxin comparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT piehlemilyc comparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT lopesvrishali comparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT dillonryanj comparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT puzniaklauraa comparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections AT laplantekerryl comparativeeffectivenessofceftolozanetazobactamversusaminoglycosideorpolymyxinbasedregimensinmultidrugresistantpseudomonasaeruginosainfections |